Related references
Note: Only part of the references are listed.The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Volker Vallon
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Robert R. Henry et al.
DIABETES CARE (2015)
Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial
Bruce A. Perkins et al.
DIABETES CARE (2014)
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
Elizabeth M. Lamos et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Immune modulation in humans: implications for type 1 diabetes mellitus
Bart O. Roep et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
William N. Washburn et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences
Ivan Sabolic et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 74 (2012)
Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
L. Chen et al.
CURRENT MOLECULAR MEDICINE (2012)
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
L. Thomas et al.
DIABETES OBESITY & METABOLISM (2012)
Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus
G. Luippold et al.
DIABETES OBESITY & METABOLISM (2012)
Early Growth Retardation and Insulin Resistance in JAZF1 KO Mice
Hui-Young Lee et al.
DIABETES (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Prediction and prevention of Type 1 diabetes mellitus
Li Zhang et al.
JOURNAL OF DIABETES (2011)
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Michael J. Jurczak et al.
DIABETES (2011)
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Jian Chen et al.
Diabetes Therapy (2010)
Preservation of beta-cell function by targeting beta-cell mass
Eelco J. P. de Koning et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes
RP Robertson
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Renal gluconeogenesis - Its importance in human glucose homeostasis
JE Gerich et al.
DIABETES CARE (2001)